Optimize IAS
  • Home
  • About Us
  • Courses
    • Prelims Test Series
      • LAQSHYA 2026 Prelims Mentorship
    • Mains Mentorship
      • Arjuna 2026 Mains Mentorship
    • Mains Master Notes
  • Portal Login
    • Home
    • About Us
    • Courses
      • Prelims Test Series
        • LAQSHYA 2026 Prelims Mentorship
      • Mains Mentorship
        • Arjuna 2026 Mains Mentorship
      • Mains Master Notes
    • Portal Login

    Convalescent Plasma Therapy

    • September 18, 2020
    • Posted by: OptimizeIAS Team
    • Category: DPN Topics
    No Comments

    Subject: Science and tech

    Context:

    Not all plasma from those who’ve recovered from COVID-19 in India may contain enough protective antibodies, says a multi-institutional study led by researchers in the country and the United States.

    Concept:

    • Convalescent plasma therapy involves transfusing certain components of blood of people who have had the Covid-19 virus and recovered to people who are sick or those at high risk of getting the virus.
    • As people fight the Covid-19 virus, they produce antibodies that attack the virus. These antibodies are secreted by immune cells known as B lymphocytes, which is found in plasma or liquid part of blood that supports immunity.
    • The US Food and Drug Administration (FDA) has already approved use of such therapy in clinical trials and for critically ill patients
    • Convalescent plasma was used in outbreaks of the H1N1 influenza virus pandemic in 2009, SARS-CoV-1 epidemic in 2003 and the MERS-CoV epidemic in 2012. It was also used to help stop outbreaks of measles and mumps before vaccines were available

    Image Source: TOI

    Convalescent Plasma Therapy Science and tech
    Footer logo
    Copyright © 2015 MasterStudy Theme by Stylemix Themes
        Search